Prime editing is a next-generation gene editing tool designed to precisely rewrite DNA—like a search-and-replace function for the human genome. In this episode, we break down how prime editing works, the chemistry behind it, and why it offers a powerful alternative to traditional CRISPR by making targeted changes without creating double-strand breaks. We also explore its applications in disease correction, its growing path toward the clinic, and the key challenges that still stand in the way.

NAMs are changing how new drugs are developed. We discuss organoids, tissue chips, and AI-based tools, along with the growing FDA and NIH push toward more human-relevant methods that can improve prediction, reduce reliance on animal models, and help bring safer treatments forward faster.

Can we grow new kidneys from stem cells? In this episode, we explore how scientists are using pluripotent stem cells to create kidney organoids that mimic early kidney development. We discuss how these mini-organs help study kidney disease, test new drugs, and move us closer to future regenerative therapies for kidney failure.

What really happens to your cells under stress, in space, and during space travel? In this episode, we zoom in on the physiological, cellular, and molecular levels to uncover how zero gravity affects them.

What does it take to grow a beating human heart in the lab? This episode explores cardiac organoids—self-organizing heart tissues derived from human stem cells that contract, respond to drugs, and model human heart disease. We unpack how iPSCs are guided into cardiac lineages, how electrical and mechanical cues drive maturation, and why these beating mini-hearts are transforming drug safety testing, disease modeling, and the future of regenerative cardiology.

In this episode, we explore the AI revolution in healthcare and what 2026 could look like—from smarter diagnostics and personalized treatments to automation that reshapes clinical workflows. We break down the key innovations, emerging trends, and real-world impact of AI on patients, clinicians, and the healthcare system.

Synthetic biology is turning cells into programmable factories, sensors, and therapies. In this episode, we explore how DNA can be engineered like code to build smarter medicines, sustainable biomaterials, and living devices—and what it will take to move these innovations from the lab to the real world.

How do you give “mini-brains” a bloodstream? This episode explores vascular brain organoids—cerebral organoids engineered with endothelial cells, pericytes, and astrocytes to form BBB-like barriers, improve oxygen/nutrient delivery, and accelerate neuronal maturation. We cover why perfusion matters for MEA activity and drug testing, how microvessels enable neurovascular-coupling studies, and what it will take to scale these tissues for translational neuroscience.

Brain organoids are self-organizing “mini-brains” grown from human stem cells that recapitulate key aspects of early neural development. They fire neural networks on MEAs, model neurodevelopmental and neurodegenerative diseases, and offer human-relevant platforms for drug discovery, circuit mapping, and studying brain evolution—while raising important questions about maturity, reproducibility, and ethics.

Grow a “mini-gut” from stem cells—fast. This episode maps the journey from pluripotent cells to functional intestinal organoids, covering key signals (Activin A, Wnt3a/R-spondin, EGF), culture formats (3D domes vs. monolayers), and core readouts (TEER, permeability, metabolism). We highlight use cases in disease modeling and drug testing.